Is the Use of SGLT-2 Associated with an Increased Risk of Cancer?

References

1. Bahl G. Upadhyay D.K. Varma M. Singh R. Das S. Hussain S. Persistent chronic calcific pancreatitis with intraductal calculi associated with secondary diabetes mellitus type 3 and diabetic ketoacidosis – A case report. Endocr. Regul. 2024 58 1 101 104 10.2478/enr‑2024‑0011 38656253
   [Google Scholar]
2. Chakrabarti K. McCune W.J. SGLT-2 inhibitors: New horizons for rheumatologists. Curr. Opin. Rheumatol. 2024 36 5 351 359 10.1097/BOR.0000000000001030 39007236
   [Google Scholar]
3. Naeimzadeh Y. Tajbakhsh A. Nemati M. Fallahi J. Exploring the anti-cancer potential of SGLT2 inhibitors in breast cancer treatment in pre-clinical and clinical studies. Eur. J. Pharmacol. 2024 978 176803 10.1016/j.ejphar.2024.176803 38950839
   [Google Scholar]
4. Ptaszynska A. Cohen S.M. Messing E.M. Reilly T.P. Johnsson E. Johnsson K. Assessing bladder cancer risk in type 2 diabetes clinical trials: The dapagliflozin drug development program as a ‘case study’. Diabetes Ther. 2015 6 3 357 375 10.1007/s13300‑015‑0128‑9 26323372
   [Google Scholar]
5. Burki T.K. FDA rejects novel diabetes drug over safety fears. Lancet 2012 379 9815 507 10.1016/S0140‑6736(12)60216‑5 22334883
   [Google Scholar]
6. Salvatore T. Galiero R. Caturano A. Rinaldi L. Di Martino A. Albanese G. Di Salvo J. Epifani R. Marfella R. Docimo G. Lettieri M. Sardu C. Sasso F.C. An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors. Int. J. Mol. Sci. 2022 23 7 3651 10.3390/ijms23073651 35409011
   [Google Scholar]
7. Dutka M. Bobiński R. Francuz T. Garczorz W. Zimmer K. Ilczak T. Ćwiertnia M. Hajduga M.B. SGLT-2 inhibitors in cancer treatment—mechanisms of action and emerging new perspectives. Cancers 2022 14 23 5811 10.3390/cancers14235811 36497303
   [Google Scholar]
8. Reilly T.P. Graziano M.J. Janovitz E.B. Dorr T.E. Fairchild C. Lee F. Chen J. Wong T. Whaley J.M. Tirmenstein M. Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus. Diabetes Ther. 2014 5 1 73 96 10.1007/s13300‑014‑0053‑3 24474422
   [Google Scholar]
9. Stottlemyer B.A. McDermott M.C. Minogue M.R. Gray M.P. Boyce R.D. Kane-Gill S.L. Assessing adverse drug reaction reports for antidiabetic medications approved by the food and drug administration between 2012 and 2017: A pharmacovigilance study. Ther. Adv. Drug Saf. 2023 14 20420986231181334 10.1177/20420986231181334 37332887
   [Google Scholar]
10. De Jonghe S. Proctor J. Vinken P. Feyen B. Wynant I. Marien D. Geys H. Mamidi R.N.V.S. Johnson M.D. Carcinogenicity in rats of the SGLT2 inhibitor canagliflozin. Chem. Biol. Interact. 2014 224 1 12 10.1016/j.cbi.2014.09.018 25289773
    [Google Scholar]
11. De Jonghe S. Johnson M.D. Mamidi R.N.V.S. Vinken P. Feyen B. Lammens G. Proctor J. Renal tubular and adrenal medullary tumors in the 2-year rat study with canagliflozin confirmed to be secondary to carbohydrate (glucose) malabsorption in the 15-month mechanistic rat study. Chem. Biol. Interact. 2017 277 85 90 10.1016/j.cbi.2017.09.008 28916336
    [Google Scholar]
12. Ahad Mir P.R.I.N.C.E. Hussain M.S. Ahmad Khanday M. Mohi-ud-din R. Pottoo F.H. Hasssan Mir R. Immunomodulatory roles of mesenchymal stem cell-derived extracellular vesicles: A promising therapeutic approach for autoimmune diseases. Curr. Stem Cell Res. Ther. 2024 20 10.2174/011574888X341781241216044130 39757602
    [Google Scholar]
13. Tang H. Dai Q. Shi W. Zhai S. Song Y. Han J. SGLT2 inhibitors and risk of cancer in type 2 diabetes: A systematic review and meta-analysis of randomised controlled trials. Diabetologia 2017 60 10 1862 1872 10.1007/s00125‑017‑4370‑8 28725912
    [Google Scholar]
14. Pelletier R. Ng K. Alkabbani W. Labib Y. Mourad N. Gamble J.M. Adverse events associated with sodium glucose co-transporter 2 inhibitors: An overview of quantitative systematic reviews. Ther. Adv. Drug Saf. 2021 12 2042098621989134 10.1177/2042098621989134 33552467
    [Google Scholar]
15. Shi N. Shi Y. Xu J. Si Y. Yang T. Zhang M. Ng D.M. Li X. Xie F. SGLT-2i and risk of malignancy in type 2 diabetes: A meta-analysis of randomized controlled trials. Front. Public Health 2021 9 668368 10.3389/fpubh.2021.668368 34164370
    [Google Scholar]
16. Chung C.T. Lakhani I. Chou O.H.I. Lee T.T.L. Dee E.C. Ng K. Wong W.T. Liu T. Lee S. Zhang Q. Cheung B.M.Y. Tse G. Zhou J. Sodium‐glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new‐onset overall cancer in Type 2 diabetes mellitus: A population‐based study. Cancer Med. 2023 12 11 12299 12315 10.1002/cam4.5927 37148547
    [Google Scholar]
17. Dicembrini I. Nreu B. Mannucci E. Monami M. Sodium‐glucose co‐transporter‐2 (SGLT‐2) inhibitors and cancer: A meta‐analysis of randomized controlled trials. Diabetes Obes. Metab. 2019 21 8 1871 1877 10.1111/dom.13745 30972917
    [Google Scholar]
18. Spiazzi B.F. Naibo R.A. Wayerbacher L.F. Piccoli G.F. Farenzena L.P. Londero T.M. da Natividade G.R. Zoldan M. Degobi N.A.H. Niches M. Lopes G. Boyko E.J. Utzschneider K.M. Colpani V. Gerchman F. Sodium-glucose cotransporter-2 inhibitors and cancer outcomes: A systematic review and meta-analysis of randomized controlled trials. Diabetes Res. Clin. Pract. 2023 198 110621 10.1016/j.diabres.2023.110621 36921905
    [Google Scholar]
19. Li Y.R. Liu C.H. Sun W.C. Fan P.Y. Liu F.H. Chen T.H. Wu V.C.C. Lin C. Hsiao C.C. The risk of bladder cancer in type 2 diabetes mellitus with combination therapy of SGLT-2 inhibitors and pioglitazone. J. Pers. Med. 2021 11 9 828 10.3390/jpm11090828 34575605
    [Google Scholar]